Shareholder Primacy

Free Float Media Inc.
undefined
Dec 17, 2025 • 1h 3min

2026 Predictions with Matt Moscardi + Damion Rallis of the Proxy Countdown podcast

2026 Predictions with Matt Moscardi + Damion Rallis of the Proxy Countdown podcast
undefined
Dec 10, 2025 • 44min

What Activists Are Doing Right Now

Mike and Ann dive into the hustle and bustle of activist work, especially during the year-end rush. They explore the three-year timeline of activism, detailing everything from analysis to results. December's significant role is highlighted, tied to fiscal year ends and proxy planning. Ann discusses strategies like targeting directors and using bylaw amendments as pressure tactics. They also touch on how boards detect activist presence and the implications of recent SEC policy changes. ESG activism concerns and its unique calendar are also examined.
undefined
14 snips
Dec 3, 2025 • 41min

Proxy Advisors and Activism

Ann and Mike delve into the evolving landscape of proxy advisors amidst legal pressures. They discuss how ISS and Glass Lewis are adapting their business models and the implications for shareholder activism. Insights include the shift from blanket recommendations to customized policies and the growing importance of analytics. The conflict between companies and proxy advisors over executive compensation comes to light, alongside the anticipated resilience of these firms in catering to loyal clients. Other topics encompass regulatory scrutiny and the impact on activism in corporate governance.
undefined
Nov 19, 2025 • 46min

Kyle Pinder on shareholder proposals under Delaware law

Mike talks with attorney Kyle Pinder about his research about shareholder proposals under Delaware law.
undefined
15 snips
Nov 12, 2025 • 36min

Legal and financial questions of Pfizer-Novo-Metsera

In a thrilling battle for MetSera, Pfizer and Novo Nordisk engage in a fierce competition driven by the value of GLP-1 drugs. The discussion delves into intricate deal structures, including cash-plus-contingent-value-right offers typical in pharma M&A. Antitrust risks loom large, with regulatory implications complicating Novo's bid strategy. The hosts dissect the legal maneuvers, and lawsuits, and unravel how litigation pressure forced Pfizer to elevate its offers. Ultimately, they ponder who emerged victorious and what lies ahead for MetSera and its shareholders.
undefined
Nov 5, 2025 • 42min

Relationship of federal and state corporation law

Ann and Mike talk about the relationship of federal and state corporate law.
undefined
Oct 29, 2025 • 36min

Universal proxy after three years

Ann and Mike talk about universal proxy after three years
undefined
Oct 22, 2025 • 45min

Shareholder proposals and Delaware law

Ann and Mike talk about SEC Chair Atkins’ speech before the Weinberg Center about shareholder proposals and their relation to Delaware law
undefined
9 snips
Oct 15, 2025 • 33min

Majority vote standards, bylaw amendments

In this discussion, hosts delve into the complexities of majority vote standard proposals and bylaw amendments. They explore Duke Energy's struggle with high charter amendment thresholds, highlighting the history of repeated shareholder initiatives. The hosts clarify the difference between precatory and binding proposals and analyze the motivations behind boards stalling shareholder-driven changes. They offer insights into the legal landscape surrounding bylaw amendments and suggest strategies for strengthening shareholder influence. A captivating exploration of corporate governance dynamics!
undefined
Oct 8, 2025 • 32min

M&A litigation, corporate personhood

Ann and Mike talk about M&A litigation in a recent important case and whether corporations are people

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app